1. CHAPTER 13 Renal Transplantation Goh Bak Leong Fan Kin Sing Rohan Malek Bin Dato’ Dr. Johan Rosnawati Yahya S. Prasad Menon Tan Si Yen Wong Hin Seng Source: 20 th MDTR Report 2012, NRR

2. Table 13.1.1:Stock and flow of renal transplantation, 1993-2012 Year199319941995199619971998199920002001 200 2 New transplant patients140204105151129106128144162172 Died24301737322829324038 Graft failure20222724354836303933 Lost to Follow up0220011522 Functioning graft at 31 st December734884943103310951124118612631344 144 3 Year200320042005200620072008200920102011 201 2 New transplant patients16219217115111113014112812294 Died41444858475949475446 Graft failure41432136 3937464241 Lost to Follow up4663121312699 Functioning graft at 31 st December151916181714176817841803184618751892 189 4 Source: 20 th MDTR Report 2012, NRR

3. Figure 13.1.1: Stock and flow of renal transplantation, 1993-2012 Source: 20 th MDTR Report 2012, NRR

4. Table 13.1.2:New transplant rate per million population (pmp), 1993- 2012 Year1993199419951996199719981999200020012002 New transplant patients140204105151129106128144162172 New transplant rate (pmp)71057656677 Year2003200420052006200720082009201020112012 New transplant patients16219217115111113014112812294 New transplant rate (pmp)6766455543 Source: 20 th MDTR Report 2012, NRR

5. Figure 13.1.2: New transplant rate, 1993-2012 Source: 20 th MDTR Report 2012, NRR 0 1 2 3 4 5 6 7 8 9 10 New Transplant rate, pmp '93'94'95'96'97'98'99'00'01'02'03'04'05'06'07'08'09'10'11'12 Year Rate, pmp

6. Table 13.1.3:Transplant prevalence rate per million population (pmp), 1993-2012 Year1993199419951996199719981999200020012002 Functioning graft at 31 st December 7348849431033109511241186126313441443 Transplant prevalence rate (pmp)3744464950 52545658 Year2003200420052006200720082009201020112012 Functioning graft at 31 st December 1519161817141768178418031846187518921894 Transplant prevalence rate (pmp)60626566 6566 65 Source: 20 th MDTR Report 2012, NRR

7. Figure 13.1.3: Transplant prevalence rate, 1993-2012 Source: 20 th MDTR Report 2012, NRR 0 10 20 30 40 50 60 70 Transplant Prevalence rate, pmp '93'94'95'96'97'98'99'00'01'02'03'04'05'06'07'08'09'10'11'12 Year Rate, pmp

8. Table 13.2.1:Renal transplant recipients’ characteristics, 1993-2012 Year1993199419951996199719981999200020012002 New Transplant Patients140204105151129106128144162172 Age at transplant (years), Mean38 35383637 394140 Age at transplant (years), SD1311 121113141312 % Male60675956645863656258 % Diabetic (co-morbid/ primary renal disease) 11121310111011161915 % HbsAg positive910713564557 % Anti-HCV positive23131619718118158 Year2003200420052006200720082009201020112012 New Transplant Patients16219217115111113014112812294 Age at transplant (years), Mean42 3837 38403837 Age at transplant (years), SD13 14151614 1513 % Male66636866645964667060 % Diabetic (co-morbid/ primary renal disease) 2321 18151820 1416 % HbsAg positive8556932443 % Anti-HCV positive10838937342 Source: 20 th MDTR Report 2012, NRR

9. Table 13.2.2:Primary causes of end stage renal failure, 1993-2012 Source: 20 th MDTR Report 2012, NRR

10. Table 13.3.1:Type of renal transplantation, 1993-2012 Source: 20 th MDTR Report 2012, NRR

11. Table 13.3.2:Place of transplantation, 1993-2012 Source: 20 th MDTR Report 2012, NRR

12. Table 13.4.1:Post-transplant complications, 1993-2012 Source: 20 th MDTR Report 2012, NRR

13. Table 13.4.2:Biochemical data, 2004-2012 Source: 20 th MDTR Report 2012, NRR

14. Table 13.4.3:Transplant patients’ death rate and graft loss, 1993- 2012 Year1993199419951996199719981999200020012002 Number at risk734809914988106411101155122513041394 Transplant death24301737322829324038 Transplant death rate %3.33.71.93.732.5 2.63.12.7 Graft loss20222724354836303933 Graft loss rate %2.7 32.43.34.33.12.43 Acute rejection0000000100 Acute rejection rate %00000000.100 All losses44524461677665627971 All losses rate %66.44.86.26.36.85.65.16.15.1 Year2003200420052006200720082009201020112012 Number at risk1481156916661741177617941825186118841893 Transplant death41444858475949475445 Transplant death rate %2.8 2.93.32.63.32.72.52.92.4 Graft loss41432136 3937464241 Graft loss rate %2.82.71.32.122.222.52.2 Acute rejection4191419142432815320 Acute rejection rate %0.31.20.81.10.81.31.84.42.81.1 All losses82876994839886939686 All losses rate %5.5 4.15.44.75.54.755.14.5 Source: 20 th MDTR Report 2012, NRR

15. Figure 13.4.3(a): Transplant recipient death rate, 1993-2012 Source: 20 th MDTR Report 2012, NRR 0.5 1 1.5 2 2.5 3 3.5 Death rate % '93'94'95'96'97'98'99'00'01'02'03'04'05'06'07'08'09'10'11'12 Year Annual death rate

16. Figure 13.4.3(b): Transplant recipient graft loss rate, 1993-2012 Source: 20 th MDTR Report 2012, NRR 0.5 1 1.5 2 2.5 3 3.5 4 4.5 Graft loss rate % '93'94'95'96'97'98'99'00'01'02'03'04'05'06'07'08'09'10'11'12 Year Annual graft loss rate

17. Table 13.4.4(a): Causes of death in transplant recipients, 1993-2012 Source: 20 th MDTR Report 2012, NRR

18. Table 13.4.4(b): Causes of graft failure, 1993-2012 Source: 20 th MDTR Report 2012, NRR

19. Table 13.5.1.1: Patient survival, 1993-2012 Interval (years)n% SurvivalSE 02879100 12553950 22357930 32162921 41959901 51783881 61603861 71409841 81208831 91020811 10872791 Source: 20 th MDTR Report 2012, NRR

20. Figure 13.5.1.1: Patient survival, 1993-2012 Source: 20 th MDTR Report 2012, NRR

21. Table 13.5.1.2: Risk factors for transplant patient survival 1993-2012 Source: 20 th MDTR Report 2012, NRR

22. Table 13.5.1.3: Graft survival, 1993-2012 Interval (years)n% SurvivalSE 0 2879100 1 2553921 2 2357891 3 2162861 4 1959831 5 1783801 6 1603771 7 1409731 8 1208711 9 1020681 10 872651 Source: 20 th MDTR Report 2012, NRR

23. Figure 13.5.1.3: Graft survival, 1993-2012 Source: 20 th MDTR Report 2012, NRR

24. Table 13.5.1.4: Risk factors for transplant graft survival 1993-2012 Source: 20 th MDTR Report 2012, NRR

25. Table 13.5.2.1:Unadjusted patient survival by type of transplant, 1993- 2012 Type of Transplant Commercial Cadaver Commercial Live Donor Cadaver Interval (years)n % Survival SEn % Survival SEn % Survival SEn %Survival SE 01252100423100745100379100 11165961383971637971285892 21127941345951588961232862 31079921297921541961194842 41005891263902485941163832 5914871243872447941142802 6844851220842394931113783 774083119380235591195773 862883118077230490183753 950081116174327288174733 1041679115272323988259713 *n=Number at riskSE=standard error Source: 20 th MDTR Report 2012, NRR

26. Figure 13.5.2.1: Patient survival by type of transplant, 1993-2012 Source: 20 th MDTR Report 2012, NRR

27. Table 13.5.2.2: Graft survival by type of transplant, 1993-2012 Type of Transplant Commercial Cadaver Commercial Live Donor Cadaver Interval (years)n % Survival SEn % Survival SEn % Survival SEn % Survival SE 01252100423100745100379100 11167941392951638921286812 21129911353911584911232762 31081891306862542901195732 41007851271822488871163703 5916821251772446861142673 6847801227722394832113633 774277119866335381296613 862974118263330178283583 950472116259326775274563 1041870115355323471259514 *n=Number at riskSE=standard error Source: 20 th MDTR Report 2012, NRR

28. Figure 13.5.2.2: Graft survival by type of transplants, 1993-2012 Source: 20 th MDTR Report 2012, NRR

29. Table 13.5.3.1: Patient survival by year of transplant (Living related transplant, 1993-2012) Year of Transplant1993-20022003-2012 Interval (years)n% SurvivalSEn% SurvivalSE 0328100278100 1298981226961 2296971197961 3285961175951 4276961141932 5271951115932 625995193892 724894167883 823893237883 922892219835 102179121835 Source: 20 th MDTR Report 2012, NRR

30. Figure 13.5.3.1: Patient survival by year of transplant (Living related transplant, 1993-2012) Source: 20 th MDTR Report 2012, NRR

31. Table13.5.3.2: Graft survival by year of transplant (Living related transplant, 1993-2012) Year of Transplant1993-20022003-2012 Interval (years)n% SurvivalSEn% SurvivalSE 0328100278100 1322902317941 2320902264921 3309872233921 4299842189892 5293832153882 6281792113852 727077283842 825773245842 924470223842 102336731777 Source: 20 th MDTR Report 2012, NRR

32. Figure 13.5.3.2: Graft survival by year of transplant (Living related transplant, 1993-2012) Source: 20 th MDTR Report 2012, NRR

33. Table 13.5.4.1: Patient survival by year of transplant (Commercial cadaver transplant, 1993-2012) Year of Transplant1993-20022003-2012 Interval (years)n% SurvivalSEn% SurvivalSE 0642100610100 1601951566961 2585931544941 3569911517921 4536881471911 5510861406891 6491841356881 7466812276872 8448812181862 943279275852 104167822852 Source: 20 th MDTR Report 2012, NRR

34. Figure 13.5.4.1: Patient survival by year of transplant (Commercial cadaver transplant, 1993-2012) Source: 20 th MDTR Report 2012, NRR

35. Table 13.5.4.2: Graft survival by year of transplant (Commercial cadaver transplant, 1993-2012) Year of Transplant1993-20022003-2012 Interval (years)n% SurvivalSEn% SurvivalSE 0642100610100 1601941566941 2585911544921 3569881517891 4536841471871 5510802406851 6491772356822 7466742276802 8448722181782 943270275772 104166722772 Source: 20 th MDTR Report 2012, NRR

36. Figure 13.5.4.2: Graft survival by year of transplant (Commercial cadaver transplant, 1993-2012) Source: 20 th MDTR Report 2012, NRR

37. Table 13.6.1: Medication data, 2004-2012 Source: 20 th MDTR Report 2012, NRR

38. Figure 13.6.1(a)(i): Calcineurin inhibitors: Cyclosporin vs Tacrolimus Source: 20 th MDTR Report 2012, NRR 0 10 20 30 40 50 60 70 80 Proportion of patients '04'05'06'07'08'09'10'11'12 Year CsATacrolimus

39. Figure 13.6.1(a)(ii): Antimetabolites: Azathioprine vs Mycophenolic Acid Source: 20 th MDTR Report 2012, NRR 0 10 20 30 40 50 60 70 Proportion of patients '04'05'06'07'08'09'10'11'12 Year AzathioprineMycophenolic Acid

40. Table 13.6.2: Use of anti-hypertensive medications Source: 20 th MDTR Report 2012, NRR

41. Table 13.7.1: Risk factors for IHD in renal transplant recipients at year 2004-2012 20042005200620072008 Diabetes27 (1.8)21 (1.4) 25 (1.6)18 (1.1) Hypertension**501 (34.1)508 (33.1)452 (30.9)586 (37.2)662 (41.7) CKD121 (8.2)142 (9.3)177 (12.1)127 (8.1)117 (7.4) Diabetes + Hypertension**149 (10.1)163 (10.6)158 (10.8)179 (11.4)204 (12.8) Diabetes + CKD21 (1.4)20 (1.3)18 (1.2)11 (0.7)22 (1.4) CKD + Hypertension**530 (36.1)537 (35.0)489 (33.4)515 (32.7)456 (28.7) Diabetes + CKD + Hypertension** 120 (8.2)143 (9.3)148 (10.1)134 (8.5)110 (6.9) 2009201020112012 Diabetes28 (1.8)35 (2.1)38 (2.2)37 (2.2) Hypertension**644 (41.0)635 (37.8)674 (38.9)596 (36.1) CKD156 (9.9)166 (9.9)159 (9.2)225 (13.6) Diabetes + Hypertension**164 (10.4)197 (11.7)215 (12.4)203 (12.3) Diabetes + CKD18 (1.1)22 (1.3)33 (1.9)33 (2.0) CKD + Hypertension**472 (30.1)514 (30.6)508 (29.3)457 (27.7) Diabetes + CKD + Hypertension** 88 (5.6)109 (6.5)105 (6.1)100 (6.1) **Hypertension: BP systolic > 140 and BP diastolic > 90, or on anti-hypertensive drugs Source: 20 th MDTR Report 2012, NRR

42. Figure 13.7.1(a): Venn diagram for pre and post transplant complications (in %) at year 2004 8,2 1.8 34.1 1.436.1 10.1 8.2 Source: 20 th MDTR Report 2012, NRR

43. Figure 13.7.1(b): Venn diagram for pre and post transplant complications (in %) at year 2006 12.1 1.4 30.9 1.233.4 10.8 10.1 Source: 20 th MDTR Report 2012, NRR

44. Figure 13.7.1(c): Venn diagram for pre and post transplant complications (in %) at year 2008 9.9 1.1 41.7 1.428.7 12.8 6.9 Source: 20 th MDTR Report 2012, NRR

45. Figure 13.7.1(d): Venn diagram for pre and post transplant complications (in %) at year 2010 9.9 2.2 37.8 1.330.6 11.7 6.5 Source: 20 th MDTR Report 2012, NRR

46. Figure 13.7.1(e): Venn diagram for pre and post transplant complications (in %) at year 2012 12.3 2.2 36.1 2.027.7 13.6 6.1 Source: 20 th MDTR Report 2012, NRR

47. Table 13.7.2(a): Systolic BP, 2004-2012 Year20042005200620072008 n%n%n%n%n% <1202081323414252162441429617 120-1293452231819398253962338422 130-1394683048029486305403262036 140-1594292745528356224122433619 160-17910261368936996795 >=180231241191171111 Year2009201020112012 n%n%n%n% <12027016348193571834618 120-12937622402214242256429 130-13965038688376513459431 140-15934420328174242237519 160-1796241015653482 >=180101 1211131 Source: 20 th MDTR Report 2012, NRR

48. Figure 13.7.2(a): Systolic BP, 2004-2012 Source: 20 th MDTR Report 2012, NRR

49. Table 13.7.2(b): Diastolic BP, 2004-2012 Year20042005200620072008 n%n%nn%n%n <805243352632632397114290853 80-846143966040589376173653731 85-89483744 5 4513 90-993212031219244152621520212 100-109564654614392231 >=110121101405050 Year2009201020112012 n%n%n%n% <80866519715292748108956 80-8453331557306293252227 85-89845114614271719 90-991971220411219111437 100-109272 1221201 >=11050403050 Source: 20 th MDTR Report 2012, NRR

50. Figure 13.7.2(b): Diastolic BP, 2004-2012 Source: 20 th MDTR Report 2012, NRR

51. Table 13.7.3: CKD stages, 2004-2012 Year20042005200620072008 n%n%n%n%n% Stage 11198 711771801116510 Stage 25793758336542345983563637 Stage 37384780549803507734675144 Stage 41137 7109711671237 Stage 5151191242231272 Year2009201020112012 n%n%n%n% Stage 116910237132271222412 Stage 260536652357543977240 Stage 377746773427724074939 Stage 41076131713371417 Stage 5221513251382 Source: 20 th MDTR Report 2012, NRR

52. Figure 13.7.3: CKD stages by year Source: 20 th MDTR Report 2012, NRR 0 20 40 60 80 100 Percent 200420052006200720082009201020112012 Year CKD Stage 1CKD Stage 2CKD Stage 3 CKD Stage 4CKD Stage 5

53. Table 13.7.4: BMI, 2004-2012 Year20042005200620072008 n%n%n%n%n% <202481627217266172621525915 20-254873146728445284742846427 25-305753761637626396533873042 > 302651729218267173191927316 Year2009201020112012 n%n%n%n% <2027216309163011528515 20-2545026500275362863332 25-3070541731397463869235 > 3028517337183591834418 Source: 20 th MDTR Report 2012, NRR

54. Figure 13.7.4: BMI, 2004-2012 Source: 20 th MDTR Report 2012, NRR 0 20 40 60 80 100 Percent 200420052006200720082009201020112012 Year BMI <20BMI 20-25 BMI 25-30BMI > 30

55. Table 13.7.5(a): LDL, 2004-2012 Year20042005200620072008 n%n%n%n%n% < 2.62871842426497315313159534 2.6-3.49626186553741467944679246 >= 3.43262135822366233832233920 Year2009201020112012 n%n%n%n% < 2.665138635346143265634 2.6-3.472742895489825193548 >= 3.433420347183461836319 Source: 20 th MDTR Report 2012, NRR

56. Figure 13.7.5(a): LDL, 1993-2012 Source: 20 th MDTR Report 2012, NRR 0 20 40 60 80 100 Percent 200420052006200720082009201020112012 Year LDL <2.6LDL 2.6-3.4LDL >= 3.4

57. Table 13.7.5(b): Total cholesterol, 2004-2012 Year20042005200620072008 n%n%n%n%n% <4.1116716010162102151321112 4.1-5.14222746028492315443254331 5.1-6.27614877747706447304373643 6.2- 7.220013174111741115991629 > 7.2116716010162102151321112 Year2009201020112012 n%n%n%n% <4.123314272143011525813 4.1-5.151330557306293266834 5.1-6.273143828447994181542 6.2- 7.21599151813871508 > 7.2764694754633 Source: 20 th MDTR Report 2012, NRR

58. Figure 13.7.5(b): Total cholesterol, 2004-2012 Source: 20 th MDTR Report 2012, NRR 0 20 40 60 80 100 Percent 200420052006200720082009201020112012 Year Total Cholesterol <4.1Total Cholesterol 4.1-5.1 Total Cholesterol 5.1-6.2Total Cholesterol 6.2-7.2 Total Cholesterol > 7.2

59. Table 13.7.5(c): HDL, 2004-2012 Year20042005200620072008 n%n%n%n%n% <18961197106711061197 1-1.32581631519302193552138722 >1.3122878121374119675124373122071 Year2009201020112012 n%n%n%n% <11539148813671357 1-1.342425412224402346124 >1.3113566131770136670135869 Source: 20 th MDTR Report 2012, NRR

60. Figure 13.7.5(c): HDL, 2004-2012 Source: 20 th MDTR Report 2012, NRR 0 20 40 60 80 100 Percent 200420052006200720082009201020112012 Year HDL <1HDL 1-1.3HDL > 1.3

61. Table 13.7.6(a): Treatment for hypertension, 2004-2012 Yearn % on anti- hypertensive drug % on 1 anti- hypertensive drug % on 2 anti- hypertensive drug % on 3 anti- hypertensive drug 200415668141319 2005163980382911 2006159975372511 2007169580343212 2008170572352710 200917017437288 201018647541248 201119247544228 201219406839236 Source: 20 th MDTR Report 2012, NRR

62. Table 13.7.6(b): Distribution of systolic BP without anti-hypertensive, 2004-2012 YearnMeanSDMedianLQUQ% Patients ≥ 160mmHg 2004262126.713.51301201324 2005295127.415.91301201404 2006356124.714.3120119.51303 2007281125.816.41231151384 200827112414.81201131303 2009337124.415.11211121302 2010397128.536.71241191375 2011414125.115.11241151313 2012569127.324.9126117.5132.52 Source: 20 th MDTR Report 2012, NRR

63. Table 13.7.6(c): Distribution of diastolic BP without anti-hypertensive, 2004-2012 YearnMeanSDMedianLQUQ% patients ≥ 90mmHg 200426278.49.680708019 200529579.19.280708119 200635677.61080708015 200728176.79.780708013 200827075.89.580708011 200933777.69.280708014 201039677.31080708215 201141477.19.280708011 201256977.61377.571.882.37 Source: 20 th MDTR Report 2012, NRR

64. Table 13.7.6(d): Distribution of systolic BP on anti-hypertensives, 2004-2012 YearnMeanSDMedianLQUQ% Patients ≥ 160mmHg 20041240133.416.41301201409 20051287134.817.213012014411 20061172132.516.41301201409 20071306132.915.91301201408 20081182130.316.81301201407 20091120131.615.91301201406 20101260130.616.21301201407 20111339131.716.11301201406 20121261132.818.3130.5123.31404 Source: 20 th MDTR Report 2012, NRR

65. Table 13.7.6(e): Distribution of diastolic BP on anti-hypertensives, 2004-2012 YearnMeanSDMedianLQUQ% Patients ≥ 90 mmHg 2004124080.79.880759027 2005128780.99.480769026 2006117279.31080708622 2007130579.29.680708521 2008116877.610.180708017 2009111878.39.580708216 2010125577.92280708214 2011133977.89.880708315 2012126178.69.979738310 Source: 20 th MDTR Report 2012, NRR

66. Table 13.8.3.1: Allograftraft and patient survival, Azathioprine vs Mycophenolic Acid 1993-2012 AzathioprineMycophenolic Acid Survival (%)nGraftPatientnGraftPatient 1 year1487100 1564100 3 years1248849110958892 5 years112977868238489 10 years86961772117282 Source: 20 th MDTR Report 2012, NRR

67. Figure 13.8.3.1(a): Graft survival, Azathioprine vs Mycophenolic Acid 1993-2012 Source: 20 th MDTR Report 2012, NRR

68. Figure 13.8.3.1(b): Patient survival, Azathioprine vs Mycophenolic Acid, 1993-2012 Source: 20 th MDTR Report 2012, NRR

69. Table 13.8.3.2: Graft and patient survival, CsA vs Tacrolimus CsATacrolimus Survival (%)nGraftPatientnGraftPatient 1 year2111100 969100 3 years140187925888791 5 years123181883948389 10 years7226680716882 Source: 20 th MDTR Report 2012, NRR

70. Figure 13.8.3.2(a): Graft survival, CsA vs Tacrolimus, 1993-2012 Source: 20 th MDTR Report 2012, NRR

71. Figure 13.8.3.2(b): Patient survival, CsA vs Tacrolimus, 1993-2012 Source: 20 th MDTR Report 2012, NRR

72. Table 13.8.3.3: Mean SBP, CsA vs Tacrolimus, 2004-2012 Mean SBP CsAMean SBP Tacrolimus 2004132.7128.7 2005134.2130.5 2006131.4127.6 2007132.6128 2008130.6125.2 2009131.3127.4 2010130.2128.1 2011131.7127.4 2012131.4129.2 Source: 20 th MDTR Report 2012, NRR

73. Figure 13.8.3.3: Mean SBP, CsA vs Tacrolimus, 2004-2012 Source: 20 th MDTR Report 2012, NRR

74. Table 13.8.3.4: Mean GFR, CsA vs Tacrolimus, 2004-2012 Mean GFR CsAMean GFR Tacrolimus 200499.3126.1 200597.3111 200697.6109.8 200796104.4 200897.3111 200995.6108.8 201091.6106.4 201190.7101.9 201292.1100.7 Source: 20 th MDTR Report 2012, NRR

75. Figure 13.8.3.4: Mean GFR, CsA vs Tacrolimus, 2004-2012 Source: 20 th MDTR Report 2012, NRR

76. Table 13.8.3.5: Mean LDL, CsA vs Tacrolimus, 2004-2012 Mean LDL CsAMean LDL Tacrolimus 20043.23 200532.8 200632.9 200732.8 20082.92.8 20092.82.7 20102.92.8 20112.9 20122.92.8 Source: 20 th MDTR Report 2012, NRR

77. Figure 13.8.3.5: Mean LDL, CsA vs Tacrolimus, 1993-2012 Source: 20 th MDTR Report 2012, NRR

78. Table 13.8.3.6: Incidence of post transplant diabetes mellitus, CsA vs Tacrolimus, 2004-2012 Post Tx DM CsAPost Tx DM Tacrolimus 20041527 20051525 20061618 20071315 200814 2009109 20101110 2011119 20121110 Source: 20 th MDTR Report 2012, NRR

79. Figure 13.8.3.6: Cumulative incidence of post transplant diabetes, CsA vs Tacrolimus, 2004-2012 Source: 20 th MDTR Report 2012, NRR

80. Table 13.9.1: Cumulative distribution of QoL-Index score in relation to dialysis modality, transplant recipient patients 1993-2012 Dialysis modalityQoL score Number of patients2227 Centile 00 0.059 0.110 0.25 (LQ)10 0.5 (median)10 0.75 (UQ)10 0.910 0.9510 1 Source: 20 th MDTR Report 2012, NRR

81. Figure 13.9.1: Cumulative distribution of QoL-Index score in relation to dialysis modality, transplant recipient patients 1993-2012 Source: 20 th MDTR Report 2012, NRR

82. Table 13.9.2: Cumulative distribution of QoL-Index score in relation to diabetes mellitus, transplant recipient patients 1993-2012 Diabetes mellitusNoYes Number of patients1954273 Centile 000 0.0597 0.1108 0.25 (LQ)10 0.5 (median)10 0.75 (UQ)10 0.910 0.9510 1 Source: 20 th MDTR Report 2012, NRR

83. Figure 13.9.2: Cumulative distribution of QoL-Index score in relation to diabetes mellitus, transplant recipient patients 1993-2012 Source: 20 th MDTR Report 2012, NRR

84. Table 13.9.3: Cumulative distribution of QoL-Index score in relation to gender, transplant recipient patients 1993-2012 GenderMaleFemale Number of patients1391836 Centile 000 0.0599 0.1109 0.25 (LQ)10 0.5 (median)10 0.75 (UQ)10 0.910 0.9510 1 Source: 20 th MDTR Report 2012, NRR

85. Figure 13.9.3: Cumulative distribution of QoL-Index score in relation to gender, transplant recipient patients 1993-2012 Source: 20 th MDTR Report 2012, NRR

86. Table 13.9.4: Cumulative distribution of QoL-Index score in relation to age, transplant recipient patients 1993-2012 Age group (years)<2020-3940-59>=60 Number of patients218944954111 Centile 00000 0.059987 0.110 98 0.25 (LQ)10 9 0.5 (median)10 0.75 (UQ)10 0.910 0.9510 1 Source: 20 th MDTR Report 2012, NRR

87. Figure 13.9.4: Cumulative distribution of QoL-Index score in relation to age, transplant recipient patients 1993-2012 Source: 20 th MDTR Report 2012, NRR

88. Table 13.9.5: Cumulative distribution of QoL-Index score in relation to year of entry, transplant recipient patients 1993-2012 Source: 20 th MDTR Report 2012, NRR

89. Figure 13.9.5: Cumulative distribution of QoL-Index score in relation to year of entry, transplant recipient patients 1993-2012 Source: 20 th MDTR Report 2012, NRR